M&A Deal Summary

Millicent Pharma Acquires AMAG Pharmaceuticals - INTRAROSA Rights

On May 21, 2020, Millicent Pharma acquired life science company AMAG Pharmaceuticals - INTRAROSA Rights from AMAG Pharmaceuticals for 125M USD

Acquisition Highlights
  • This is Millicent Pharma’s 1st transaction in the Life Science sector.
  • This is Millicent Pharma’s largest (disclosed) transaction.
  • This is Millicent Pharma’s 1st transaction in the United States.
  • This is Millicent Pharma’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2020-05-21
Target AMAG Pharmaceuticals - INTRAROSA Rights
Sector Life Science
Buyer(s) Millicent Pharma
Sellers(s) AMAG Pharmaceuticals
Deal Type Divestiture
Deal Value 125M USD

Target

AMAG Pharmaceuticals - INTRAROSA Rights

Waltham, Massachusetts, United States
INTRAROSA is a vaginal non-estrogen treatment for moderate to severe painful sex due to menopause. It is made with a plant-derived form of DHEA combined with coconut and palm oils.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Millicent Pharma

Dundalk, Ireland
Category Company
Founded 2018
Sector Life Science
DESCRIPTION

Millicent Pharma is a pharmaceutical company that is focused on improving patient lives and outcomes and seeks to acquire, develop, manufacture, and commercialize pharmaceutical products globally. Millicent Pharma was founded in 2018 and is based in Dundalk, Ireland.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

AMAG Pharmaceuticals

Waltham, Massachusetts, United States
Category Company
Founded 1981
Sector Life Science
Employees440
Revenue 328M USD (2019)
DESCRIPTION

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse. AMAG Pharmaceuticals was formed in 1981 and is based in Waltham, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-12-13 Perosphere Pharmaceuticals

Danbury, Connecticut, United States

Perosphere Pharmaceuticals, Inc. is a private clinical-stage company focused on developing rescue drugs. Perosphere Pharma's lead investigational drug product candidate, ciraparantag (PER977), is an FDA Fast Track designated, intravenously administered small synthetic water-soluble new molecular entity intended for use as a reversal agent for the orally administered direct Factor Xa inhibitors and low molecular weight heparin.

Buy -
Mergr

Product

Company

Legal